Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on November 10, 2021. The filing serves to announce the Company's financial results for the quarter ended September 30, 2021. The Company is designated as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the source text provided.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended September 30, 2021.
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. Such information is contained within the referenced press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2021) for specific Q3 2021 financial figures.
- Verify the Company's cash position and burn rate as reported in the full press release.
- Confirm any updates to clinical trial progress or commercialization milestones mentioned in the referenced exhibit.
- Check for any new debt covenants or liquidity events disclosed in the full text of the press release.